CSL Ltd (CSLLY) Price

GeoVax Trial Data Challenges mRNA Vaccine Efficacy

GeoVax announced its COVID-19 vaccine, GEO-CM04S1, showed superior T-cell responses in CLL patients versus Pfizer's mRNA vaccine. The trial's independent monitoring board recommended stopping the comparator arm, signaling a significant clinical validation for GeoVax's platform.